Treatment with tolebrutinib led to greater confirmed disability improvement at 6 months compared with placebo in patients ...
Patients with relapsing MS treated with tolebrutinib vs teriflunomide had a clear reduction in disability accumulation with no difference in relapses.
The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application for tolebrutinib for the treatment of non-relapsing ...
A decision on tolebrutinib for treating MS is now set for Sept. 28, after the FDA granted priority review to its approval ...
Zacks Investment Research on MSN9d
FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Revised)Sanofi SNY announced that the FDA has accepted its regulatory filing seeking approval for its investigational BTK inhibitor ...
The FDA review – which is due to be completed by 28th September – revolves around the results of the HERCULES trial which ...
Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosisIf approved, tolebrutinib would be ...
Sanofi SNY announced that the FDA has accepted its regulatory filing seeking approval for its investigational BTK inhibitor tolebrutinib ... progressive multiple sclerosis (nrSPMS) and slow ...
If approved, tolebrutinib would be the first and only brain-penetrant BTK inhibitor to both treat non-relapsing secondary progressive multiple sclerosis (MS) and slow disability accumulation ...
Sanofi SNY announced that the FDA has accepted its regulatory filing seeking approval for its investigational BTK inhibitor tolebrutinib ... progressive multiple sclerosis (nrSPMS) and slow ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback